þ subsets; allogeneic HSC transplantation; CB; BM; PBPC; allografts Allogeneic stem/progenitor transplantation (SCT) is the treatment of choice for selected patients suffering from certain hematological malignancies and inherited disorders. [1] [2] [3] A prerequisite for this treatment modality is the ability to predict safe hematopoietic reconstitution by calculating the yields of total nucleated cells (TNCs) in bone marrow (BM) and cord blood (CB) allografts, and of CD34 þ cells in mobilized peripheral blood (PB) allografts. However, neither of these end points are direct measures of lineage-committed and pluripotent hematopoietic progenitor cells (HPCs) that affect short-and long-term engraftment following allogeneic SCT. Hence, the ability to predict the speed of clinical recovery and the quality of long-term reconstitution might be improved by direct enumeration of distinct progenitor subsets in allografts.
Pluripotent human HPCs are defined as cells having both the capacity for self-renewal and the ability of sustained differentiation into all mature hematopoietic lineages. They have been characterized as CD34 þ subsets that coexpress CD90 (Thy-1) 4 and lack differentiation-associated antigens such as HLA-DR and CD38, 5, 6 largely through in vitro assays and their ability for durable multilineage engraftment in immune-deficient mice and in fetal sheep. [6] [7] [8] In contrast to pluripotent HPCs, lineage-committed HPCs have been characterized as CD34 þ CD38 þ cells, which coexpress the following lineage-restricted antigens: CD33 (myeloid), CD15 (late myeloid), CD64 (granulomonocytic), CD71 (erythroid), CD61 (megakaryocytic), CD7 (T cell), and CD19 (B-cell). [9] [10] [11] [12] [13] [14] In addition, myeloid-committed HPCs have been defined as colony-forming cells (CFCs), owing to their ability to form colonies of fully mature myeloid cells (CFU-GM, BFU-E, CFU-GEMM) in semisolid clonogenic assays after 10-18 days. Studies of human and murine HPCs have recently demonstrated that transplanted myeloid CD34 þ subsets highly enriched for CFCs rapidly differentiated into mature cells in vivo, which corresponded to their cell fate outcome in the colony assays. Moreover, myeloid CD34 þ subsets highly enriched for CFCs demonstrated an early transient engraftment from the first to the fourth week post transplant, whereas pluripotent HPCs initiated sustained multilineage engraftment after 3 weeks. 8, 15, 16 These findings indicate that myeloid HPCs, that is, CFCs, contribute to the early neutrophil and platelet recovery before pluripotent HPCs take over, and provide sustained multilineage engraftment.
In the allogeneic transplant setting, BM and PB grafts collected from donors are generally transplanted within 2 days, whereas CB grafts are cryopreserved for later use. This tight schedule of allogeneic SCTs precludes the clinical use of in vitro and in vivo assays for HPC enumeration, as they need several weeks of incubation before read-out. Thus, flow cytometry is currently the only available method in clinical use for the assessment of distinct progenitor subsets in allografts.
In the light of the above findings, we assessed myeloidcommitted and pluripotent CD34 þ subsets in single LPs, BM, and CB allografts collected on a clinical scale by threecolor flow cytometry analysis. In addition, we report a new gating strategy for the enumeration of pluripotent CD34 þ CD38 À cells.
Materials and methods

Collection of allografts
CB allografts, BM allografts, and LPs were collected on a clinical scale as described previously. 17, 18 Samples from allografts were obtained and analyzed immediately after the completion of collection. All samples were obtained following informed consent according to the guidelines established by the Ethics Committee of the Cities of Copenhagen and Fredricksberg.
Cell enumeration and flow cytometry analysis
Total nuclear cell (TNC) enumeration was performed by microscopy, using a Neubauer improved hemocytometer and methylviolet staining. The enumeration of CD34 þ cells was carried out on whole BM, CB, and LP samples, and samples of mononuclear cells (MNCs) obtained by density separation (Lymphoprep, density 1.077 g/ml, Nycomed Pharma AS, Oslo, Norway), as described previously. 19 Pluripotent and myeloid-commited HPCs were characterized by the following CD34 þ subsets. Early-as well as late-myeloid HPCs including all CFCs express CD33, whereas CD15 is expressed only on late-myeloid progenitors. 9, 10 Hence, early-myeloid HPCs were defined as CD34 þ CD33 þ CD15 À and late-myeloid HPCs as CD34 Figure 1a ). The CD71 antigen (transferrin receptor) is present at intermediate levels on proliferating myeloid progenitors including early-erythroid progenitors and at high levels on late-erythroid HPCs, whereas CD64 (Fcg-receptor I) is restricted to the granulomonocytic lineages. 11, 12 Thus, CD34 þ CD71 high CD64 À cells were defined as late-erythroid HPCs and CD34 þ CD71 low CD64 þ cells as granulomonocytic HPCs (Figure 1b ). Pluripotent HPCs are highly enriched in the CD34 þ CD38 À population of CB and BM. 20, 21 In addition, pluripotent HPCs derived from CB have been reported to express the HLA-DR antigen, 22, 23 whereas pluripotent adult HPCs have low or absent HLA-DR expression. 5 Pluripotent HPCs were subcategorized into þ cells (range 2369-6000 cells) were acquired into a CD34 live gate based on fluorescence intensity (FI) and SSC level, accepting 0.1% false-positive events in control samples. CD34 þ subset analysis was performed using the CellQuest software (BDIS) (Figure 1 ). By backgating the CD34 þ population in the FSC vs SSC dot plot, only events of lymphoblastoid character were accepted for analysis. For isotype control analysis, the percentage of false-positive events accepted in the respective control samples was within the range of 0.9-1.1% for each fluorescence. Yields of CD34 þ subsets were calculated by multiplying frequencies of CD34 þ subsets and total numbers of CD34 þ cells in allografts (assessed by analysis of unseparated samples). This approach was accepted for the quantitation of CD34 þ subsets, as previous data demonstrated no selective loss of distinct subsets in the MNC fraction when compared to unseparated samples. 24 
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Colony assay
Myeloid HPCs were further enumerated by the CFC assay. Briefly, whole allograft samples were plated directly in duplicate (35 Â 10 mm dish, NUNC, Roskilde, Denmark) at concentrations of 1.0, 0.5, and 0.25 Â 10 5 TNCs/ ml in semisolid medium (StemCell Technologies Inc., Vancouver, Canada, composition: 0.9% methylcellulose, 30% fetal calf serum, 1% bovine serum albumin, 2 mM Lglutamine, 3 U/ml EPO, 50 ng/ml rhSCF, 20 ng/ml rhGM-CSF, 20 ng/ml IL-3, 20 ng/ml IL-6, 20 ng/ml rhG-CSF). Cultures were incubated for 18 days in a water-saturated atmosphere of 5% CO 2 at 371C. Plates with more than 30 colonies and less than 70 colonies were selected for the calculation of colony numbers. Colonies were classified as CFU-GM, CFU-GEMM, and BFU-E by inverted microscopy. 24 The total number of CFCs in allografts was calculated as the sum of all CFU-GM, CFU-GEMM, and BFU-E.
Statistics
The GraphPad software (San Diego, CA, USA) was used for statistical analysis. Results are expressed as mean 7standard error of mean (s.e.m.). Statistical significance was determined by the two-tailed Mann-Whitney test. Linear regression analysis was used to evaluate the correlation of CD34 þ CD38 À frequencies detected by isotype control analysis and MFI-threshold analysis. A significance level of Po0.05 was chosen.
Results
TNCs, CFCs, and CD34
þ cells
The contents of TNCs, total CFCs (including all CFU-GM, BFU-E, and CFU-GEMM), and CD34 þ cells in allografts are depicted in Table 2 . In general, yields of each cell type were significantly lower in CB grafts than BM grafts and single LPs due to the limited amount of CB collectable from one placenta (Tables 2-4 ). Absolute numbers of TNCs and CFCs were slightly but significantly higher in single LPs than in BM grafts ( Table 2) .
HPCs compared to CB and LPs (Table 3 ). In contrast, early-myeloid HPCs (CD34 þ CD33 þ CD15 À ) were detected at higher frequencies in the CD34 þ populations of LPs and CB than in BM (Table 3) . Thus, BM grafts contained significantly higher amounts of late-myeloid HPCs, but lower amounts of early-myeloid HPCs than single LPs, whereas CB grafts provided significantly lower amounts of all myeloidcommitted CD34
þ subsets (26-65 Â ) than grafts from adult donors (Table 3) .
Early-committed and pluripotent CD34
þ subsets
Frequencies of early-committed CD34 þ CD90 þ CD38 low subsets were similar in all graft types, whereas frequencies of pluripotent CD34 Total CFCs contents represent the sum of CFU-GM, CFU-GEMM, and BFU-E contents. 
CD38
À HLA-DR þ ) were significantly higher within the CD34 þ compartment of CB compared to that of BM and LPs (Table 4 ). The contents of pluripotent CD34 þ
À subsets, however, were 8-12-fold lower in CB grafts than in BM grafts and LPs (Table 4) .
Correlation of TNCs, CD34
þ cells, and myeloid-committed CD34 þ subsets with CFCs
Since early neutrophil and platelet engraftment are potentially affected by CFCs, 15, 16 we investigated whether the contents of TNCs, CD34 þ cells, and CD34 þ subsets were predictive for the contents of total CFCs in allografts. When analyzing the three graft types together and individually, the contents of pluripotent CD34 þ CD38 Figure 3) were not predictive for the contents of total CFCs. In contrast, the contents of CD34 þ cells and early-myeloid CD34 þ CD33 þ CD15 À subsets correlated equally well with the contents of total CFCs for all types of allografts ( Figure 3) . Notably, the TNC 
Significant P-values are marked by an asterix, and P-values with a trend towards significance (between 0.08 and 0.05) are written in paranthesis. ns ¼ non significant.
contents of BM grafts and CB grafts but not LPs correlated well with the contents of total CFCs (Figure 3) . However, the TNC contents were less predictive for total CFC contents in BM and CB grafts compared to the contents of CD34 þ and early-myeloid CD34 þ
CD33
þ CD15 À subsets (Figure 3 ). Additional analysis by paired t-test revealed that the contents of CD34 þ cells and CFCs differed significantly in BM grafts and CB grafts but not in LPs (BM: P ¼ 0.0001, CB: P ¼ 0.038, LPs: P ¼ 0.186), whereas the contents of early-myeloid , and P-value. ns ¼ non significant.
À subsets and CFCs were similar in all types of grafts (BM: P ¼ 0.318, CB: P ¼ 0.758; LP: P ¼ 0.187). These findings demonstrate that, among all tested parameters, the early-myeloid CD34 þ CD33 þ CD15 À subset is the most accurate estimate of CFC contents in allografts.
MFI-based gating strategy for enumeration of pluripotent HPCs Figure 2 depicts À subsets between 0.5 and 6% (Figure 2) . Notably, the frequencies of CD34 þ CD38 À subsets were significantly lower in LPs than in BM grafts and CB grafts for each category of MFI-threshold gates (LP vs BM/CB: Pp0.02, BM vs CB: PX0.3).
For all the three types of grafts, distinct categories of MFI-threshold gates (BM: 3%, CB: 7%, LP: 5%) allowed the detection of CD34 þ CD38 À subset frequencies similar to those detected by conventional isotype control analysis (Figure 2) . Moreover, the CD34 þ CD38 À subset frequencies assessed by the two different gating strategies correlated significantly for each type of allograft ( Figure 2 ). These findings indicate that MFI analysis using MFI-threshold gates of 3% (BM), 7% (CB), and 5% (LP) could substitute for isotype control analysis when enumerating pluripotent HPCs in allografts.
Discussion
The aim of this study was to assess the contents of HPCs capable of hematopoietic short-and long-term reconstitution in LPs, BM allografts, and CB allografts. HPCs can be subcategorized through in vitro and in vivo assays, and phenotypically through CD34 þ subset analysis. In the allogeneic transplant setting, however, CD34 þ subset analysis is the only method of clinical use for HPC enumeration, given the time delay before the read-out of functional assays. Despite this fact, our study is the first that compares the contents of distinct CD34 þ subsets in commonly used types of allografts collected on a clinical scale. However, a few studies on comparison of CD34 þ subsets from different cell sources have been published. 11, 19, 25 In line with those studies, pluripotent CD34 þ subsets were detected at significantly higher frequencies in the CD34 þ compartment of CB compared to that of BM and LPs. À subsets compared to adult stem cell sources. The latter suggests that the protracted clinical recovery following CB transplantation is not affected essentially by the low amount of early-myeloid HPCs, but rather by pluripotent HPCs. Hence, the content of pluripotent HPCs, that is, CD34 þ CD38 À subsets, and not early-myeloid HPCs is likely to be an important parameter for the prediction of safe clinical reconstitution in CB transplantation.
Additional regression analysis revealed that, for each type of allograft, the numbers of CD34 þ cells and earlymyeloid CD34 þ CD33 þ CD15 À subsets were the most predictive parameters for the numbers of CFCs. The CD34 þ cell numbers, however, were generally higher than those of CFCs, and differed significantly in BM and CB grafts. In contrast, the numbers of earlymyeloid CD34 þ CD33 þ CD15 À subsets were similar to CFC numbers in all graft types. Hence, among all tested parameters, the early-myeloid CD34 þ CD33 þ CD15 À subset provided the most accurate measure of the total CFC content in allografts. The latter is in accordance with previous studies demonstrating that almost all human CFCs coexpress CD34 þ and CD33 þ antigens. 9, 16 In addition, these findings indicate that the dose of earlymyeloid CD34 þ CD33 þ CD15 À subsets might correlate better than the TNC dose with time to clinical recovery following BM transplantation. This potential of early-
À subsets, however, needs to be tested prospectively in a series of transplanted patients.
Analysis of progenitor subsets by flow cytometry is a technical challenge, as most CD34 þ subsets do not form distinct antigen-positive or -negative cell clusters, but rather have a wide range of antigen densities. These antigen densities can be detected by flow cytometry as the FI of cells stained with antigen-specific MoAbs conjugated with fluorochromes. Currently, the most commonly used protocols define cells stained with antigen-specific MoAbs as positive for the respective antigen, when they have an FI above cells stained with isotype-matched unspecific control MoAbs. Alternatively, the threshold for positive/negative subsets can be defined based on antigen density rather than the unspecific binding capacity of control MoAbs. This can be accomplished by calibration with quantitative FI standards, that is, fluorochrome-conjugated beads, and subsequent definition of an FI threshold for positive/ negative subsets within a population stained by a specific MoAb. 27 We reasoned that a simpler strategy based on antigen density would be to use an internal FI standard such as the MFI of a population stained with a specific MoAb to discriminate between CD34 À subset analysis based on antigen densities. Moreover, the application of MFI analysis to cells with abnormal CD38 antigen densities due to sample processing or malignancy should be avoided due to erroneous gating of CD34 þ CD38 À subsets. However, when analyzing fresh samples from healthy individuals, the MFI gating strategy presented here is an attractive alternative for the enumeration CD34 þ CD38 À subsets, owing to its simplicity and its potential for implementation in protocols for CD34 þ subset analysis based on multiparameter Boolean gating. 28 In summary, our data indicate that the generally observed faster clinical recovery following transplantation of LPs as compared to BM allografts is not due to a different content of pluripotent HPCs, but rather to the higher content of early-myeloid HPCs in LPs. We further demonstrate that the enumeration of early-myeloid CD34 þ CD33 þ CD15 À subsets provides an accurate measure of the CFC contents in various types of allografts. Finally, this study reports a new gating strategy that can be used in lieu of conventional isotype control analysis for the enumeration of pluripotent CD34 þ CD38 À subsets.
